X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
EBO-301 (epetraborole) is a boron-containing oral inhibitor of bacterial leucyl-tRNA synthetase. It is being developed for treatment-refractory mycobacterium avium complex lung disease.
Lead Product(s): Epetraborole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EBO-301
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
AN2-501971 (epetraborole) is a boron-containing, orally-available, small molecule inhibitor of bacterial leucyl-tRNA synthetase, or LeuRS, an enzyme, which is investigated for the treatment of refractory mycobacterium avium complex lung disease.
Lead Product(s): Epetraborole
Therapeutic Area: Infections and Infectious Diseases Product Name: AN2-501971
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, Demonstrates Potent Efficacy and Improves Efficacy of Standard of Care Regimen Against Mycobacterium avium complex in a Chronic Mouse Lung Infection Model.
Lead Product(s): Epetraborole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AN2-501971
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
Results of the study of AN2-501971 (epetraborole) showed that no subjects experienced treatment-emergent adverse events and support use of AN2’s recommended dose in Japanese patients enrolled in its ongoing Phase 2/3 study.
Lead Product(s): Epetraborole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AN2-501971
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
The base period contract is ammend to support the preclinical, Phase 1 studies and other activities to enable advancement of epetraborole (AN2-501971) into a pivotal Phase 2/3 clinical trial for acute systemic melioidosis.
Lead Product(s): Epetraborole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AN2-501971
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: $17.8 million Upfront Cash: Undisclosed
Deal Type: Funding September 29, 2022
Details:
As a once-daily oral therapy, epetraborole (AN2-501971), has the potential to become an important component of a multi-drug treatment regimen for patients with treatment-refractory MAC lung disease.
Lead Product(s): Epetraborole
Therapeutic Area: Infections and Infectious Diseases Product Name: AN2-501971
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
AN2-501971 (epetraborole) inhibits bacterial leucyl tRNA synthetase IND cleared, received Qualified Infectious Disease Product and Fast Track Designation from FDA for the treatment of refractory Mycobacterium avium complex lung disease.
Lead Product(s): Epetraborole
Therapeutic Area: Infections and Infectious Diseases Product Name: AN2-501971
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2022
Details:
The financing is expected to support advancement of AN2’s development candidate epetraborole, a once-daily, orally administered investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM).
Lead Product(s): Epetraborole
Therapeutic Area: Infections and Infectious Diseases Product Name: AN2-501971
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
